Centrum Medyczne Uno-Med Sp. z o.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The centre is running studies that focus on ulcerative colitis, aiming to compare a new biosimilar with an established biologic and to test a novel antibody for inducing remission.
- Comparison of the biosimilar AVT16 to Entyvio in moderate to severe active ulcerative colitis
- Evaluation of vixarelimab versus placebo for clinical remission induction
- Assessment of long‑term safety and tolerability in ulcerative colitis participants
- Investigation of pharmacokinetics and treatment response in inflammatory bowel disease
Located in Tarnow, Poland, the site engages four investigators across six trials, contributing to advances in gastrointestinal therapeutics.
Eye Diseases
Research at the facility includes trials for diabetic macular edema and age‑related macular degeneration, testing innovative intravitreal therapies and long‑term safety of complement inhibitors.
- Long‑term safety and efficacy of pegcetacoplan in geographic atrophy secondary to AMD
- EYP‑1901 intravitreal insert compared with aflibercept for visual acuity improvement
- Treatment evaluation for wet age‑related macular degeneration using novel agents
- Study of visual outcomes and disease progression in diabetic macular edema patients
The hospital’s ophthalmology team collaborates with four investigators, delivering six clinical studies that aim to enhance eye‑health outcomes across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eyepoint Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyepoint Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Medyczne Uno-Med Sp. z o.o.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 3 | Unknown | 2023-09-13 | 2026-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.